A5054223542- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Cancer survivorship and care
- Childhood Cancer Survivors' Quality of Life
- Peptidase Inhibition and Analysis
- Cancer, Hypoxia, and Metabolism
- Bone Tumor Diagnosis and Treatments
- Renal cell carcinoma treatment
- Sarcoma Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Oral and Maxillofacial Pathology
- Cancer-related cognitive impairment studies
- Cancer-related Molecular Pathways
- Protein Degradation and Inhibitors
- Adolescent and Pediatric Healthcare
Thomas Jefferson University
2023-2024
Thomas Jefferson University Hospital
2021-2024
Sidney Kimmel Cancer Center
2023
Outpatient chemotherapy often leaves patients to grapple with a range of complex side effects at home. Leveraging tailored evidence-based content monitor and manage these symptoms remains an untapped potential among gastrointestinal (GI) cancer.This study aims bridge the gap in outpatient care by integrating cutting-edge text messaging system chatbot interface. This approach seeks enable real-time monitoring proactive management GI cancer undergoing intravenous chemotherapy.Real-Time...
PURPOSE Pancreatic adenocarcinoma is an aggressive disease with poor clinical outcomes. Primary pancreatic tumors originating from the head of pancreas (H) have different prognostic implications than arising body and tail (BT). This thought to be largely due anatomic differences, as molecular underpinnings survival not been fully explored. We hypothesized that differences in primary site H BT might account for differential outcomes response chemotherapy. METHODS Retrospective data a single...
694 Background: TP53 is a commonly mutated tumor suppressor in pancreatic adenocarcinoma (PDAC) but the clinical implications for different classes of variants remain unclear. In contrast to loss function (LOF) mutations, gain (GOF) mutations alter DNA conformational binding (e.g. R175H, G245S, R249S, R282H) or modify contact hotspots R248Q, R248W, R273H) and are associated with aggressive phenotypes. Here, we analyze progression-free survival (PFS) on standard therapies overall (OS) PDAC...
4159 Background: More than 50% of patients with Pancreatic ductal adenocarcinoma (PDAC) have metastatic disease at the time diagnosis and liver is most common site spread. Liver metastasis (LM) associated poor prognosis. Herein we examine difference in molecular landscape PDACs LM versus other sites (OM). Methods: Total 7,979 PDAC tumors underwent next-generation sequencing DNA (592-gene/whole exome) RNA (whole transcriptome) Caris Life Sciences (Phoenix, AZ). Tumors were then evaluated...
<sec> <title>BACKGROUND</title> Outpatient chemotherapy often leaves patients to grapple with a range of complex side effects at home. Leveraging tailored evidence-based content monitor and manage these symptoms remains an untapped potential among gastrointestinal (GI) cancer. </sec> <title>OBJECTIVE</title> This study aims bridge the gap in outpatient care by integrating cutting-edge text messaging system chatbot interface. approach seeks enable real-time monitoring proactive management GI...